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ABSTRACT
In 2012 it was estimated that one in every nine Americans over the age of 65 has
Alzheimer’s disease (AD) (1).

These patients experience gradual loss of memory,

cognition, and behavioral stability eventually leading to death (2). These symptoms were
first described in 1906 by Alois Alzheimer and now are the classic signs of the number
one neurodegenerative disease today.

Current AD therapies delay or mitigate the

symptoms associated with AD to improve the quality of life for the patient; however,
there is currently no cure for those that have been diagnosed. In order to develop a
possible treatment for patients with mild to severe AD, the disease pathology must first
be understood. One neuropathological marker for AD is the development of amyloid
plaques, which are deposited around the neurons in the brain and are associated with
neuronal atrophy. The main constituents of these plaques are aggregated forms of the
amyloid-β (Aβ) peptide. Thus, one possible therapeutic intervention for AD is to inhibit
the formation of Aβ aggregates.
Numerous small molecules and peptides have been studied for their ability to
inhibit Aβ aggregation, but none have proven therapeutically effective. In this study, we
demonstrated the effects of two novel inhibitors of Aβ aggregation. First, we examined
the ability of spherical gold nanoparticles (NP) with varying diameter and surface
coatings to abrogate Aβ aggregation. Results indicated that smaller NPs with an anionic
poly acrylic acid (PAA) surface coating were the most effective as inhibitors of
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aggregation at concentrations as low as 20 pM. Peptoids, mimicking the hydrophobic
core of Aβ, were also studied for their ability to inhibit Aβ aggregation. Peptoids of
similar structure, but differing in a single charged residue, induced the formation of
fewer, smaller oligomeric Aβ aggregates.

Additionally, inclusion of a neutral or

positively charged residue in the peptoid sequence induced structural changes in Aβ1-42
oligomers. Overall, this study provides insight into the effective properties of gold NPs
and peptoids as novel potential inhibitors of Aβ aggregation.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
1.1. Alzheimer’s Disease
Every 68 seconds another person in the United States develops Alzheimer’s
disease (AD). In 2012, it was estimated that 5.4 million Americans were afflicted by AD
(1). Currently, AD ranks as the sixth leading cause of death in the United States;
however, it is expected to increase as the number of people diagnosed increases every
year (1). These patients experience gradual loss of memory, cognition, and behavioral
stability eventually leading to death (2). In 1906, Alois Alzheimer described to the
scientific community a disease in which patients were disoriented and exhibited
deteriorating long-term memory and communication skills as well as a gradual loss of
their ability to form and maintain short-term memories. Post mortem autopsies of the
brains of Alzheimer’s patients showed severe neuronal atrophy along with an increased
presence of intraneuronal neurofibrillary tangles (NFTs) and extracellular amyloid
plaques, which have become the two pathological hallmarks of this disease (3).
NFT’s are paired helical filaments that form from the hyperphosphorylation of the
tau protein. Under normal conditions, tau serves in the promotion of tubulin assembly
and the stabilization of microtubules in neurons. As a result of the disregulation of the
phosphorylation cascade, tau assembles into insoluble filamentous polymers that deposit
as NFTs within neurons in the brain (4).
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These tangles are also observed in

patients with other neurological diseases, such as Pick’s disease and Parkinson-dementia
complex of Guam (5). Thus, while these NFTs lead to cellular atrophy in the brain, they
are not the defining causative agent in AD pathology (6). According to the amyloid
cascade hypothesis (Figure 1.1), hyperphosphorylated tau deposition and subsequent
tangle pathology is caused by a chain of events that stems from changes in the
metabolism of the amyloid-β (Aβ) protein.

1.2. Amyloid-β Protein
Aβ, the main constituent of amyloid plaques, was first isolated by Glenner et al. in
1984 (7).

With varying isoforms ranging from 40-42 residues, Aβ is a naturally

occurring protein in the body, whose function is still unknown.

It is produced via

cleavage of the amyloid precursor protein (APP), a 695 residue protein, also with
uncertain functions, found in neuronal and non-neuronal cells throughout the body (8).
Cleavage of APP at two sites leads to the formation of the more abundant Aβ1-40 (9) or
the more pathogenic Aβ1-42 (10). Cleavage of Aβ from APP can occur via two pathways
(Figure 1.2).

In both pathways C-terminal transmembrane cleavage by γ-secretase

generates Aβ1-40 or Aβ1-42 depending on the location of cleavage (11).

γ-secretase

cleavage occurs due to the aspartyl protease complex, whose main components are
presenilin 1 (pres1) and presenilin 2 (pres2) (5). Scheuner et al. have demonstrated that
AD causing mutations in pres1 or pres2 cause an increase in the production of Aβ1-42
(12). N-terminal cleavage via β-secretase releases the amyloidogenic Aβ. However,
alternative cleavage by α-secretase results in the non-amyloidogenic fragment P3. In
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Figure 1.1: The amyloid cascade hypothesis (13)
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mice lacking the β-site APP-cleaving enzyme (BACE-1), the production of Aβ is halted
and only P3 species are produced (14).
The amyloid plaques commonly found in AD brains are primarily composed of
insoluble amyloid fibrils. These fibrils form due to the aggregation of Aβ from its
monomeric state. Aβ aggregation occurs as a nucleation dependent process exhibiting
lag, growth and plateau phases (Figure 1.3A). The rate limiting lag phase occurs when
Aβ monomer spontaneously forms a nucleus (15). Once nucleation has taken place, Aβ
aggregate growth begins, proceeding to soluble aggregates and finally insoluble fibrils.
Soluble aggregates are ~5 nm in diameter with an average length of 150 nm (16). The
development of soluble aggregates into fibrils can occur via two simultaneous growth
mechanisms: elongation and association (17).

In soluble aggregate elongation,

monomeric Aβ binds to the ends of the aggregates increasing their length. Alternatively,
soluble aggregate association occurs when two or more aggregates laterally bind to one
another creating an aggregate with increased radius (Figure 1.3B). Finally, in the plateau
phase, equilibrium is reached among all Aβ species.

1.3. Inflammation and AD
Aβ aggregation and deposition is associated with an increase in inflammatory
responses. As stated in the amyloid cascade hypothesis (Figure 1.1), Aβ deposition leads
to the activation of brain astrocytes and microglia (13), followed by an increase in
pro-inflammatory molecules, such as cytokines, chemokines and complement proteins
(18). This increase in pro-inflammatory molecules in turn brings on a cyclic process of
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Figure 1.2: APP cleavage pathways: Cleavage of APP by β-secretase and γ-secretase to
create Aβ1-40 or Aβ1-42. Alternate cleavage by α-secretase creates the non-amyloidogenic
P3 species.
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Figure 1.3: Aβ aggregation: A) Aβ aggregation begins with a rate-limiting nucleation
lag phase, followed by growth of soluble aggregates and a plateau where fibrils, soluble
aggregates, and monomers are in equilibrium. B) Monomeric Aβ assembles into a
nucleus which grows to form soluble aggregates. These soluble aggregates can then
elongate or associate to form insoluble fibrils.
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inflammation, leading to further activation of astrocytes and microglia, which leads to the
further production of pro-inflammatory molecules (19).
One key molecule in AD-associated inflammation is nuclear factor-κB (NF-κB).
NF-κB is a heterodimer comprised of p65 and p50 subunits that plays a central role in
inflammatory regulation (20; 21). Under normal conditions, NF-κB is bound by IκB,
which restricts its location to the cytoplasm. When cellular activation occurs, such as an
increase in pro-inflammatory molecules, IκB is phosphorylated, releasing NF-κB to
translocate into the nucleus where it begins transcription of a variety of inflammatory and
immune related genes (Figure 1.4) (22).
Aβ has been shown to induce NF-κB activation in neuronal cells (23-27). To
further elucidate the role of Aβ in NF-κB activation, researchers have examined the
effects of different Aβ aggregate species. He et al. examined the effects of fibrillar and
oligomeric Aβ1-42 on NF-κB activation in male rats. While both species were found to
increase activation compared to control rats, oligomeric Aβ increased activation beyond
that of the fibrillar Aβ (28). In corroboration with these results, Gonzalez-Velasquez et
al. also observed increased NF-κB activation in human brain microvascular endothelial
cells by soluble Aβ1-40 but not fibrillar Aβ1-40 (29).

1.4. Inhibition of Aβ Aggregation
While it was originally postulated that insoluble Aβ fibrils were the pathogenic
species, later research suggests that the soluble intermediate aggregates are most toxic
(30).

Correlations between the degree of neuronal dysfunction and the number of

amyloid plaque deposits in the brain proved weak. However, it was later observed that
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Figure 1.4: Activation of NF-κB: NF-κB is a heterodimer comprised of p65 and p50
subunits. Under resting conditions NF-κB is bound by IκB, restricting its location to the
cytoplasm. When cellular activation occurs, such as an increase in pro-inflammatory
molecules, IκB is phosphorylated, releasing NF-κB. Once NF-κB is released, it
translocates into the nucleus where it begins transcription of a variety of inflammatory
and immune related genes.
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neuronal dysfunction correlated with the concentration of soluble Aβ species found in
AD brains (31). In addition, neuronal death in cultured cells is induced when cells are
treated with soluble Aβ (32). Thus, the ability to inhibit or alter the formation of these
species may be imperative to disease therapies.
Inhibition of Aβ aggregation can occur at multiple steps. The first stage at which
inhibition can occur is during nucleation, where inhibitors can bind to individual
monomeric units stopping them from coalescing, or impede already formed nuclei from
growing.

Inhibition can also occur during soluble aggregate growth blocking

mechanisms of either association or elongation. During association, inhibitors can bind
to the side of the aggregates, blocking lateral binding. During elongation, inhibitors can
bind either to the free monomers or to the ends of aggregates to block monomer addition.

1.5. Therapeutic Applications of Nanoparticles in Alzheimer’s Disease
The biological application of nanoparticles (NP) has gained interest over the years
for cellular imaging and targeted gene and drug delivery (33). NPs can range in size
from a few nanometers up to hundreds of nanometers and can be synthesized from a wide
variety of materials such as metals, polymers, lipids and carbon (34). In AD research,
NPs are being investigated as potential biosensors for the detection of AD biomarkers.
Aβ derived diffusible ligands (ADDL’s), which are an Aβ oligomeric species, are
expected to be enriched in cerebrospinal fluid (CSF) of AD patients. Haes et al. created a
biosensor that can determine ADDL concentration based on a shift of the localized
surface plasmon resonance (LSPR) of gold nanotriangles. As the ADDL’s bind to the
sensor, the LSPR wavelength shifts to the right, which can correlate to ADDL
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concentration in the CSF (35). Another potential biomarker for AD is ApolipoproteinE
(ApoE).

Ratios between total ApoE and isoform ApoE4 are significantly different

between patients with and without AD. To examine the ability to increase biomarker
detection over conventional methods, such as enzyme-linked immunosorbent assays
(ELISA), researchers investigated the use of core-shell quantum dots (QD) as reporters
for microarrays to increase assay sensitivity. In this study it was determined that the
QD’s could increase ApoE detection by 7-fold over traditional ELISA (36).
An imperative feature of any treatment candidate for neurodegenerative diseases
is the ability to cross the blood brain barrier (BBB). The BBB, consisting of endothelial
cells and astrocytic feet, serves as the transportational gateway to protect the brain from
infection. For this reason, transport across the barrier is severely restricted. To bypass
this restriction, NP-mediated delivery can carry across the BBB a drug either encased
within the NP or bound to its surface (37; 38). Recently, Veiseh et al. have synthesized
iron oxide derived NPs coated with a tumor targeting drug that can successfully cross the
BBB and bind to tumors within a mouse model (39). In another study, the transportation
across the BBB of bare and peptide conjugated NPs was examined. While both types of
NPs were found to successfully transport, their mechanisms of action were different.
Although the transport mechanism for peptide conjugated NPs was uncertain, it was
discovered that bare NPs undergo macropinocytosis to cross the BBB (40).

1.6. Potential Therapeutic Application of Peptoids in Alzheimer’s Disease
One of the key features of Aβ aggregation is the protein’s ability to bind itself.
This suggests the existence of a specific binding domain within the protein that allows for
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aggregation. To determine this binding region, researchers have evaluated the ability of
Aβ fragments to aggregate in a manner similar to as the full length protein (41-44).
These studies demonstrated that fragments based on the hydrophobic core of Aβ
aggregate with the same propensity as the full length protein, implicating the
hydrophobic core as the key region associated with Aβ aggregation. With this notion in
mind, researchers have investigated the ability to disrupt aggregation using peptides as
inhibitors. Some studies have examined the effect of peptides, mimicking the C-terminus
of Aβ, which is proposed to play a critical role in the formation of Aβ structure during
aggregation (45-47). In particular, Fradinger et al. demonstrated that Aβ39-42 and Aβ31-42
both alter Aβ1-42 aggregate structure and reduce Aβ1-42 induced neurotoxicity in cultured
mouse primary hippocampal cells (45).

Studies have also examined the effects of

peptides designed from the N-terminus of Aβ. Findeis et al. examined multiple peptides
designed from Aβ with and without cholyl modification. Screening results showed that
Aβ1-15 and Aβ16-30 were able to arrest aggregation, and this effect was enhanced with
cholyl modification (48).
While peptides derived from the sequence of Aβ have shown promise as potential
aggregation inhibitors, peptides are susceptible to proteolysis when introduced to the
body, leading to ineffective results as potential therapeutics. One approach to circumvent
this problem is the use of peptoids. Peptoids were originally designed to maintain
polypeptide structure while removing their susceptibility to degradation (49).

This

structural stability was accomplished by creating structures where the side-chain
connectivity point is moved from the α-carbon to the amide nitrogen (Figure 1.5).
Movement of the side-chains leads to two distinct advantages for peptoids over peptides.
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Figure 1.5: Schematic comparison of peptide and peptoid structure: Side chain
connectivity is moved from the α-carbon to the backbone nitrogen. This results in the
ability of peptoids to be resistant to proteolysis and increased flexibility of the backbone.
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First, protease degradation is eliminated, and secondly, movement of the side-chain
allows for greater flexibility of the peptoid (50). These two advantages combined make
peptoids a novel therapeutic agent for Aβ aggregation with strong potential.
In this study, nanoparticles and peptoids were examined for their effects as novel
Aβ aggregation inhibitors. Nanoparticles, which have the ability to cross the BBB, have
potential as strong therapeutic agents in AD. Their ability to attenuate aggregation of
Aβ1-40 was examined and is outlined in Chapter 4. Another potential therapeutic in AD is
the use of peptoids, due to their strong resistance to proteolysis. We examined the effects
of a neutral charge peptoid on Aβ1-42 oligomerization along with its ability to alter Aβinduced NF-κB activation (Chapter 5).

Finally, to further elucidate the effects of

peptoids, charge modulation of this peptoid was examined in Chapter 5 to determine if
charge can alter the effects of the peptoids on Aβ1-42 oligomerization and NF-κB
activation (Chapter 6).
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CHAPTER 2
MATERIALS & METHODS
2.1. Materials
Aβ1-40 and Aβ1-42 were purchased from AnaSpec, Inc. (San Jose, CA).
Thioflavin T (ThT), Triton-X 100, sodium chloride (NaCl), sodium hydroxide (NaOH),
phosphate buffered saline (PBS), paraformaldehyde, 1,1,1,3,3,3-Hexafluoro-2-propanol
(HFIP), phenazine methosulfate (PMS) and 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino)carbonyl]-2H tetrazolium hydroxide (XTT) were purchased from Sigma
(St. Louis, MO). Dulbecco’s modified Eagle's medium (DMEM), Ham’s F12K medium,
fetal bovine serum (FBS), sodium bicarbonate, penicillin, streptomycin, glycine,
pyruvate, β-mercaptoethanol, and Fluoroshield with 4’, 6’-diamidino-2-phenylindole
dihydro-chloride (DAPI) were also obtained from Sigma. Bovine serum albumin (BSA)
and dimethyl sulfoxide (DMSO) were obtained from EMD Biosciences (San Diego, CA).
Uranyl acetate and 300 square mesh formvar-carbon supported copper grids were
obtained from Electron Microscopy Sciences (Hatfield, PA). Donkey normal serum was
obtained

from

Jackson

Immunoresearch

(West

Grove,

PA).

8-Anilino-1-

naphthalenesulphonic acid (ANS) was obtained from Research Organics (Cleveland,
Ohio).

Surfact-Amps 20 detergent (Tween) and SuperSignal West Pico enhanced

chemiluminescent

substrate

(ECL)

were
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purchased

from

Thermo

Fisher

Scientific (Rockland, IL). Recombinant human tumor necrosis factor-α (TNF-α) was
obtained from Promega (Madison, WI).
Antibodies were purchased from the following companies: rabbit anti-NF-κB-p65
antibody from Rockland (Gilbertsville, PA); rabbit anti-Aβ-fibrils antibody (LOC) from
EMD Millipore (Billerica, MA); mouse anti-Aβ1-16 antibody (6E10) from Covance
(Princeton, NJ); goat anti-rabbit IgG AlexaFluor 633 conjugate from Life Technologies
(Carlsbad, CA); goat anti-rabbit IgG horseradish peroxidase (HRP) conjugate from BioRad (Hercules, CA); and sheep anti-mouse IgG HRP conjugate from GE Healthcare
(Piscataway, NJ).

2.2. Aβ1-40 Monomer Purification
When studying Aβ1-40 aggregation, it is important to ensure that aggregation
reactions are initiated with only monomeric species, since small aggregates can accelerate
aggregation kinetics by serving as nucleation seeds. Thus, Aβ1-40 monomer was purified
using size exclusion chromatography (SEC). Lyophilized Aβ1-40 peptide was stored
desiccated at -20 °C. As described previously (51), the peptide was reconstituted to a
concentration of 2 mg/mL in 50 mM NaOH to dissociate preformed small aggregates. To
reduce nonspecific interactions between Aβ1-40 and the column matrix, the Superdex 75
10/300 GL column (GE Healthcare) column was pre-treated with 2 mg/mL BSA before
injection of solubilized Aβ1-40. Using 40 mM Tris-HCl (pH 8.0) elution buffer, a void
peak (8-12 mL) containing Aβ1-40 aggregates was followed by monomer, which elutes
within the included volume at approximately 15-19 mL (Figure 2.1). The concentration
of eluted monomer was determined using a Beckman Coulter DU700 UV-VIS

15
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Figure 2.1: Purification of Aβ1-40 monomer: Aβ1-40 monomer is separated from small
aggregates using SEC on Superdex 75. Aβ1-40 aggregates elute from the column within
the void peak (8-12 mL), while Aβ1-40 monomer elutes in the included volume between
15-19 mL.

16

spectrometer (Brea, CA) at λ=276 nm with an extinction coefficient (ε) of 1450 cm-1M-1
(17). Purified monomeric Aβ1-40 was stored at 4˚C for no longer than 7 days.

2.3. Preparation of Aβ1-40 Fibrils
Insoluble Aβ1-40 fibrils were prepared from SEC isolated Aβ1-40 monomer. As
described previously (51), 60-70 µM monomeric Aβ1-40 was agitated at 25°C for 24 h in
the presence of 250 mM NaCl and 40 mM Tris-HCl (pH 8.0). Fibrils were separated
from soluble Aβ1-40 species via centrifugation (14,000 xg, 10 min).

Supernatant,

containing unreacted monomer and soluble aggregates, was removed and the pellet was
resuspended in 40 mM Tris-HCl (pH 8.0). Fibril concentration was calculated from the
fraction of pelleted protein. Fibrils were stored at 4°C for no longer than 7 days.

2.4. Aβ1-40 Monomer Aggregation
Aggregation of Aβ1-40 monomer was carried out with 400 μL reactions containing
20 μM SEC-isolated Aβ1-40 monomer, 150 mM NaCl, and 40 mM Tris-HCl (pH 8.0)
incubated alone (positive control) or in the presence of potential inhibitors (experimental
samples). Reactions were incubated at room temperature (25 °C) and agitated at 800 rpm
to promote Aβ1-40 aggregation. The extent of aggregation was determined using ThT
fluorescence or dot blot analysis.

2.5. Analysis of Aβ1-40 Monomer Aggregation with ThT
ThT is a benzathiole dye that binds to the β-sheet structure of amyloid aggregates
but does not bind to unordered species, including monomer (52). When ThT is bound to
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β-sheet aggregates it experiences a shift in fluorescence excitation and emission
wavelengths and an enhancement in fluorescence emission (53). To determine the extent
of monomer aggregation reactions, a 20 μL sample was periodically removed from each
reaction and combined with 140 μL of 10 μM ThT. Fluorescence was measured using an
LS-45 luminescence spectrometer (Perkin-Elmer, Waltham, MA) with excitation at
450 nm and emission at 460-520 nm.

Fluorescence values were determined by

integrating the area under the emission curve from 470-500 nm and subtracting the
baseline (ThT alone). Results are plotted as fluorescence vs. time, and experimental
samples are compared to the control.

2.6. Analysis of Aβ1-40 Monomer Aggregation by Dot Blot
To determine the extent of monomer aggregation reactions by dot blot analysis, a
4 μL sample was periodically removed from each reaction, dotted onto 0.1 μm
nitrocellulose membrane, and allowed to dry. After each time point the membrane was
blocked until the aggregation reaction was completed (≥1 h) at 4ºC in 5% nonfat milk in
PBS with Tween (PBS-T). Primary antibody LOC (1:5000) in 5% nonfat milk in PBS-T
was allowed to incubate for 1.5 hrs followed by three washes in PBS-T. HRP-conjugated
anti-rabbit secondary antibody (1:2000) in 5% nonfat milk in PBS-T was allowed to bind
for 1.5 hrs. The immunolabeled protein membrane signal was enhanced using ECL and
imaged with the Gel DocTM XRS+ imaging system (Biorad). Blots were analyzed using
Biorad Quality One software with identical area elements for each protein dot. Density
values for each dot were calculated as percent of control to allow for comparison between
blots and experiments.
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2.7. Quantitative Analysis of Aβ1-40 Monomer Aggregation
To evaluate inhibition, Aβ1-40 aggregation in the presence of each potential
inhibitor was quantitatively compared to the positive control. Extension of the lag, which
occurs prior to aggregation, indicates the ability of an inhibitor to slow nucleation. Lag
extension was calculated as the ratio of the time at which aggregation signal first
increases for the experimental sample (tE) relative to that of the control (tC) (Equation 2.1,
Figure 2.2). A lag extension of 1 denotes no change from the control.

Equation 2.1
Reduction of the equilibrium plateau, which occurs at the conclusion of aggregation,
indicates the ability of an inhibitor to decrease the quantity of aggregates containing
β-sheet structure present at equilibrium.

Plateau reduction was calculated as the

percentage decrease in the average plateau signal observed for each experimental sample
(SE) relative to that observed for the control (SC) (Equation 2.2, Figure 2.2). A plateau
reduction of 0% denotes no change from the control.

Equation 2.2
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Aggregation

SE

SC

tC
tE

Time

Figure 2.2: Assessment of inhibition of Aβ1-40 monomer aggregation: Monomer
aggregation assays were performed in the absence (control, solid line) and presence
(experimental, dashed line) of potential inhibitors, and aggregate formation was followed
by ThT fluorescence or dot blot analysis to evaluate the ability of the potential inhibitors
to alter lag time and plateau equilibrium. Lag time extension was evidenced as an
increase in the experimental lag time, tE, as compared to the lag time for the control, tC,
and determined by the ratio, tE/tC. Reduction of the equilibrium plateau was evidenced as
a decrease in the average experimental plateau, SE, relative to the average plateau
observed for the control, SC, and was determined as the percentage decrease from the
control, [(SC – SE)/SC] x 100%.
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2.8. Transmission Electron Microscopy
Monomer aggregation reactions were gridded for transmission electron
microscopy (TEM) at time points after which the control reaction reached equilibrium. A
10 µL sample was placed on a 300 square mesh formvar-carbon supported copper grid.
After 3 min, the sample was wicked away from the bottom side of the grid using a piece
of filter paper. Sample application was repeated twice in this manner, and samples were
allowed to air dry for 24 h. Gridded samples were stained with 2% aqueous uranyl
acetate for 10 min, excess stain was wicked away, and the grids were allowed to dry for
24 h. Imaging was performed using a JEOL 200CX TEM (JEOL Ltd., Tokyo, Japan)
with an accelerating voltage of 120 kV. Blinded observation of samples with random
selection of grid areas was implemented to reduce bias during imaging.

2.9. ThT Detection of Aβ1-40 Aggregates in the Presence of Potential Inhibitors
Employing ThT for the detection of amyloid aggregates containing β-sheet
structure is a well established technique in the field (53; 54). However, when using ThT
to monitor the effects of a potential inhibitor on Aβ1-40 aggregation, interference in the
fluorescent signal can occur (55). A false increase in fluorescent signal can be observed,
due to self-fluorescence of the inhibitor, leading to the inability to identify inhibition. On
the other hand, potential inhibitors can exhibit strong absorbent properties in the range at
which ThT emission occurs, which leads to a quenching of the fluorescent signal and
false positive results.
To identify any alterations in ThT fluorescence due to potential inhibitors, the
ThT fluorescence of pre-formed Aβ1-40 fibrils was evaluated in the presence of potential
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inhibitors.

Aβ1-40 fibrils were diluted in 40 mM Tris-HCl (pH 8.0) to a final

concentration of 5 µM either with or without the inclusion of inhibitor and combined
with 8.75 µM ThT to reflect concentrations within diluted samples used to monitor Aβ1-40
aggregation. Fluorescence was measured at 0 h and 2 h using a BioTek Synergy 2
microplate reader (Winooski, VT) with excitation at 450 nm and emission at 485 nm.
ThT fluorescence was found to be compromised if a significant difference in fluorescent
signal was observed between samples with and without the addition of inhibitor.

2.10. Preparation of Aβ1-42 Oligomers
Lyophilized Aβ1-42 was stored desiccated at -80 °C until use.

Aβ1-42 was

dissolved in cold HFIP at a concentration of 4 mg/mL and allowed to incubate for
60 min. After incubation, the peptide solution was aliquoted, and the HFIP was allowed
to evaporate at room temperature resulting in the creation of thin peptide films. Once
dry, peptide films were stored desiccated at -80 °C until use. Prior to experimentation,
peptide films were rehydrated in DMSO to a concentration of 1.5 mM and incubated
alone (positive control) or in the presence of potential inhibitor (experimental sample).
PBS with 1 µM NaCl was added for a final Aβ1-42 concentration of 20 µM. Reactions sat
quiescent at 25 °C for 30 min at which point they were halted by the addition of 1%
Tween.

2.11. Analysis of Aβ1-42 Oligomerization via SDS-PAGE and Western Blotting
Aβ1-42 oligomers formed in the absence or presence of potential inhibitors were
separated by size via sodium dodecyl sulfate polyacrylamide gel electrophoresis
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(SDS-PAGE). After the reaction was halted via addition of 1% Tween, samples were
diluted 1:1 with lamelli or tricine loading buffer and electrophoresed at 120 V across
4-20% Tris-Glycine or 16.5% Tricine gels, respectively. Following separation, protein
was transferred to 0.2 μm nitrocellulose membrane via semi-dry blot transfer on a Transblot SD semi-dry transfer cell (Biorad) for 15 min at 14 V. Membranes were blocked for
1 h in 5% nonfat milk in PBS-T. Primary antibody, 6E10 (1:1000) in 5% nonfat milk in
PBS-T, was allowed to incubate for 1 h followed by three washes in PBS-T. HRPconjugated anti-mouse secondary antibody (1:2000) and Precision Protein StrepTactinHRP conjugate (1:5000) in 5% nonfat milk in PBS-T were allowed to bind for 45 min.
Immunolabeled protein membrane signal was enhanced using ECL and imaged using the
Gel DocTM XRS+ imaging system (Biorad). Blots were analyzed using Biorad Quality
One software with identical area elements for each range (20-100 kDa and 100-250 kDa)
of molecular weights. Density values for each range were calculated as percent of
control to allow for comparison between blots and experiments.

2.12. Determination of Aβ1-42 Oligomer Structure by ANS Fluorescence
ANS is a naphthaline based compound commonly used as a fluorescent probe.
When ANS is introduced to solvent exposed hydrophobic residues it undergoes a
conformational change resulting in both blue shift and increased quantum yield (56).
ANS was solubilized in DMSO at a concentration of 50 mM and stored at 4 °C. Stock
ANS was diluted with PBS and then combined with oligomers without the addition of
Tween for final concentrations of 100 μM ANS and 1 μM Aβ1-42. Fluorescence was
measured using a LS-45 luminescence spectrophotometer (Perkin Elmer, Waltham, MA)
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with excitation at 350 nm, emission from 400 nm to 600 nm, and excitation and emission
slits of 10 nm. Fluorescence values were determined as the integrated area under the
emission curve from 400 nm to 550 nm with background (buffer or inhibitor with ANS)
subtraction.

2.13. Cell Culture
Human neuroblastoma SH-SY5Y cells (American Type Culture Collection,
Manassas, VA) were maintained in a 1:1 mixture of DMEM and Ham’s F12K medium
supplemented with FBS (10%), penicillin (100 Units/mL), and streptomycin
(100 μg/mL). Medium was changed every 48 hrs and cells were split 1:3 when they
reached 80% confluency. All cultures were maintained at 37 °C in a humid atmosphere
of 5% CO2 and 95% air.

2.14. XTT Reduction Assay
The neurotoxicity of inhibitor candidates was assessed using XTT reduction to
evaluate cellular metabolic activity of SH-SY5Y cells, as XTT reduction is known to
correlate with direct measures of Aβ-induced cellular toxicity (57). When metabolically
active cells are treated with XTT, a colored formazan derivative is formed, which can be
detected via absorbance (58). Inclusion of PMS facilitates cellular uptake of XTT.
SH-SY5Y cells were sustained as in Section 2.13 until experimentation. Cells were
seeded 5x104 cells/well onto 96 well plates using reduced serum medium, containing 1%
FBS, and allowed to reach a semi-confluent state (24 h). Cell culture medium was
replaced with medium into which inhibitors were diluted, and cells were incubated for
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24 h. Cells incubated with medium alone served as a negative control, while cells
incubated with a 2% Triton X-100 in culture medium served as a positive control.
Following 24 h exposure, cells were washed, treated with 0.33 mg/mL XTT in the
presence of 8.3 µM PMS diluted in cell culture medium, and incubated for 24 h.
Absorbance at 450 nm, used to detect the soluble formazan XTT reduction product, was
measured using a BioTek Synergy 2 microplate reader.

Results are reported as a

percentage of the positive control following background (medium containing XTT)
subtraction.

2.15. Confocal Microscopy of NF-κB Activation in SH-SY5Y Cells
SH-SY5Y cells were seeded onto 22x22 mm uncoated glass coverslips, and
allowed to adhere for 24 hrs. Cells were treated for 15 min with Aβ1-42 oligomers formed
in the absence or presence of potential inhibitor without the addition of Tween.
Following treatment, cell cultures were washed, fixed in 3% paraformaldehyde and
permeabilized with 0.1% Triton X-100 and 0.01 M glycine in PBS. Cells were then
blocked with 5% normal donkey serum and 1% BSA in PBS and incubated overnight
(4 °C) with rabbit anti-NF-κB-p65 (1:500). Cells were again blocked with 5% normal
donkey serum and 1% BSA in PBS and bound primary antibody was detected via 2 h
incubation with goat anti-rabbit IgG AlexaFluor 633 conjugate (1:1000). Coverslips
were mounted onto slides using Fluoroshield containing DAPI for nucleic visualization.
Image z-stacks were collected with optimal interval settings using a Zeiss LSM 510
META confocal microscope (Carl Zeiss, Thornwood, NY) with either a plan-apochromat
63X / 1.4 oil DIC or 40X / 1.3 oil immersion objective (Carl Zeiss). Images were
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collected with identical settings. Blinded observation of samples with random selection
of imaging areas was implemented to reduce bias during imaging.

2.16. NF-κB Quantification with MATLAB
Custom MATLAB (MathWorks, Natick, MA) functions developed previously
were implemented to quantify image data for each confocal optical series (59). First,
nuclear areas were defined as the pixels in DAPI channel images with fluorescence
greater than the optimal background, determined separately for each experiment. Total
nuclear volumes within the z-stack were calculated from the total nuclear voxel count and
the voxel size. Second, the nuclear NF-κB fluorescence was defined as the sum of
fluorescence values for all pixels within NF-κB channel images colocalized to a nuclear
area. Results were calculated as the total nuclear NF-κB fluorescence per nuclear volume
and are reported as the mean ± standard error (SEM) for 3 optical series.

2.17. Statistical Analysis
Statistical analysis was performed using Prism 5 software (GraphPad Software
Inc., San Diego, CA). The effect of potential inhibitors on extension of the lag time
reduction of the equilibrium plateau, neurotoxicity, and oligomer size were evaluated
using a one-way analysis of variance. Differences between experimental groups and
controls were assessed using Dunnett’s test. Inhibitor effects on ThT interference were
evaluated using a two-way analysis of variance, with Bonferroni posttests, to identify
differences between experimental groups and controls.
significant.
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p<0.05 was considered

CHAPTER 3
SIZE AND SURFACE MODIFICATIONS OF GOLD NANOPARTICLES INFLUENCE INHIBITION OF
Aβ AGGREGATION
3.1. Introduction
A wide array of compounds, including fluorescent dyes (60; 61), peptides (62;
63), and small molecules (64; 65), have shown positive results in disrupting the formation
of Aβ aggregates. However, none have been as effective as NPs at substoichiometric
ratios, a characteristic that will facilitate delivery of therapeutically effective
concentrations to the brain (64; 66). This potential of NPs to serve as AD therapeutics
necessitates insight into the properties of NPs that impart effective inhibitory capabilities.
While each material used to create NPs has its own advantages and disadvantages, gold
NPs are therapeutically desirable since they are non-toxic (67), can cross the BBB (38),
and the size and shape of synthesized particles can be uniformly controlled (68). Gold
NPs are also desirable for their ability to be imaged using electron microscopy (69). In
addition, gold NPs absorb and scatter light in the visible region (70). This latter attribute
leads to a strong surface plasmon band which varies with particle size and shape (71),
which makes these NPs easy to characterize.
Many studies have examined the effects of NPs on amyloid aggregation. Bellova
et al. demonstrated that Fe3O4 magnetic NPs can inhibit the formation of lysozyme
amyloid aggregates.

These particles were also shown to depolymerize preformed

aggregates (72). Previous studies using various inorganic NPs have shown the ability to
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diminish the formation of amyloid aggregates. Using copolymeric NPs at picomolar
concentrations, Cabaleiro-Lago et al. demonstrated retardation of fibrillation during islet
amyloid polypeptide (IAPP) aggregation, which was dependent upon particle surface
chemistry (73). Applying the same copolymeric particles, Cabaleiro-Lago et al. also
observed a concentration dependent extension of lag time for Aβ monomer aggregation,
indicative of inhibition of nucleation (74). Yoo et al. synthesized cadmium-tellurium
(CdTe) NPs stabilized with thioglycolic acid (TGA) that dose dependently prolonged
Aβ1-40 nucleation and decreased the quantity of aggregates formed. These results were
evidenced with ratios of CdTe NPs to Aβ1-40 as low as 0.001 (75).
However, the effects of gold NPs on Aβ aggregation have not been examined as
extensively as other particle types. Kogan et al. used local heat dissipated from gold NPs
stimulated by an electromagnetic field to induce the disaggregation of preformed amyloid
fibrils as well as to prohibit the formation of new fibrils (76). Liao et al. examined the
effect of charged gold nanospheres on Aβ fibrilization and demonstrated that negatively
charged NPs were able to reduce the formation of Aβ fibrils (77). From these studies the
potential of gold NPs as Aβ aggregation inhibitors is evidenced however, the
characteristic of these NPs that impart strong inhibitory capabilities are still
undetermined.
In this study, the effects of surface chemistry and diameter on the ability of
spherical gold NPs to inhibit Aβ aggregation were investigated. Gold NPs coated with
cationic, CTAB and PAH, and anionic, citrate and PAA, were examined to determine if
surface charge and surface chemistry influence inhibitory capabilities toward Aβ
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aggregation. In addition, 8 nm, 18 nm, and 40 nm diameter spherical NPs were evaluated
to determine if NP size alters the NP-protein interactions.
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3.2. Materials & Methods
3.2.1. Nanoparticle Synthesis
Gold NPs were obtained from the laboratories of Dr. Catherine Murphy
(Department of Chemistry, University of Illinois at Urbana-Champaign) and Dr. Rahina
Mahtab (Department of Biological and Physical Sciences, South Carolina State
University). NPs used in this study were synthesized with a spherical shape and 8 nm,
18 nm, or 40 nm diameter. Capping agents of interest in this project were sodium citrate
and PAA, which impart an anionic surface charge, and CTAB and PAH, which induce a
cationic surface charge (Figure 3.1). Citrate NPs were synthesized according to the Frens
method (78), where HAuCl4 was heated to a boil and reduced using sodium citrate,
creating monodisperse suspensions of gold NPs. CTAB, PAA and PAH surface coated
NPs, were synthesized via a seeding growth protocol (79).

3 nm citrate NPs were

synthesized by the reduction of HAuCl4 by sodium borohydride and then capped with
sodium citrate. These particles served as nucleation centers that were used to grow larger
particles. Seed diameter was increased by the reduction of HAuCl4 and CTAB with
ascorbic acid. Once the CTAB particles were created to the desired size, PAA and PAH
were coated on to the particles to yield the desired surface capping agent. Particle
concentration was determined from UV absorbance at λ=520 nm using an extinction
coefficient that is independent of the capping ligand (80), but is a function of the particle
diameter (D).

Equation 3.1
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Figure 3.1: NP structure: Citrate stabilized NPs were synthesized using the classical
Frens method. For the synthesis of CTAB, PAA, and PAH-coated NPs, a seeding growth
protocol was implemented where each NP layer is overcoated onto the previous layer.
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3.2.2. Aβ1-40 Monomer Aggregation
To assess NP inhibitory capabilities monomer aggregation experiments were
conducted as described in Section 2.4, with slight modification.

Due to unwanted

aggregation of the NPs stimulated by high salt concentrations, reactions were performed
in 40 mM Tris-HCl, in the absence of NaCl, and at an Aβ1-40 concentration of 40 μM to
promote protein aggregation. NPs were evaluated for their inhibitory capabilities at
concentrations ranging from 20 pM-200 pM.

Aggregation was assessed via ThT

fluorescence as described in Section 2.5, with data analysis as described in Section 2.7,
and by TEM analysis as described in Section 2.8.

3.2.3. ThT Detection of Aβ1-40 Aggregates in the Presence of Gold NPs
The possibility that NPs may interfere with the ThT fluorescent signal was
evaluated as described in Section 2.9.

NPs were assessed for ThT interference at

concentrations ranging from 5 pM-200 pM.

3.2.4. XTT Reduction Assay
Cellular viability following exposure to gold NPs was assessed via XTT reduction
as described in Section 2.14. SH-SY5Y human neuroblastoma cells were cultured as
described in Section 2.13 and treated with NPs at either 100 pM or 200 pM.
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3.3. Results
3.3.1. Neurotoxicity of Surface Coated NPs
When developing a potential therapeutic agent, it is important to determine that it
will be toxicologically inert. NPs were evaluated for their ability to induce toxicity in
SH-SY5Y human neuroblastoma cells. SH-SY5Y cells, cultured in low serum medium,
were incubated for 24 h alone or in the presence of 100 pM or 200 pM NPs. When
metabolic activity was assessed using an XTT reduction assay, cellular viability remained
>95% following incubation with 18 nm NPs displaying citrate, PAA, and PAH surface
chemistries (Figure 3.1). In contrast, 18 nm NPs displaying CTAB surface chemistry
reduced cellular metabolic activity by 81.2±7.2% and 85.0±5.7% at 100 pM and 200 pM,
respectively, indicating their ability to induce neurotoxicity. When SH-SY5Y cells were
incubated in the presence of PAA-coated NPs with varying diameter, 8 nm and 18 nm
NPs failed to elicit toxicity while 40 nm NPs were neurotoxic, reducing cellular viability
by 90.7±2.5% and 90.6±0.1% at 100 pM and 200 pM, respectively (Figure 3.2).

3.3.2. Effect of Surface Coated NPs on ThT Fluorescence Detection of Aβ1-40
Aggregates

The plasmonic nature of NPs imparts an ability to absorb and scatter light, which
may quench or enhance fluorescent signals (81). To ensure that observed differences in
ThT fluorescence accurately reflect changes in β-sheet aggregate formation, ThT
fluorescence of pre-formed Aβ1-40 aggregates was measured in the absence and presence
of NPs.

Representative of concentrations in diluted samples used for monitoring

33

XTT Reduction
(% Control)

A

100

50
***

***

PA
H

18
nm

PA
A
nm

18

18

18

nm

C
TA
B

at
e
C
itr

nm

Tr

ito
nX

0

XTT Reduction
(% Control)

B
100

50
***
***

A
nm
40

18

PA

A
PA
nm

nm
8

Tr

ito

n-

X

PA
A

0

Figure 3.2: Neurotoxicity of surface coated NPs: SH-SY5Y human neuroblastoma
cells were incubated for 24 h alone or in the presence of 100 pM (closed bars) or 200 pM
(open bars) 18 nm NPs (A) or 8 nm, 18 nm and 40 nm PAA-coated NPs (B). Treatment
with Triton-X served as a positive control. Cellular viability was assessed using XTT
reduction. Results represent the mean of 2-3 independent experiments, each performed
with 6 replicates. Error bars represent SEM. *** p < 0.001 compared to control.
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aggregation reactions, 5 µM Aβ1-40 fibrils were incubated for 2 h with 8.75 µM ThT and
5-200 pM NPs, and ThT fluorescence was compared to Aβ1-40 fibrils incubated with ThT
alone.

ThT fluorescence detection of Aβ1-40 fibrils was unaltered by 18 nm NPs

displaying citrate, PAA, and PAH surface chemistries (Figure 3.3A). In contrast, 18 nm
CTAB-coated NPs significantly quenched ThT detection of aggregated Aβ1-40 at
concentrations of 50 pM and higher. When PAA-coated NPs of varying diameter were
compared, neither 8 nm nor 18 nm NPs altered the detection of Aβ1-40 fibrils by ThT;
however, ThT detection was significantly compromised by the presence of 40 nm PAAcoated NPs (Figure 3.3B). As a result of these findings, assessment of the effect of
18 nm CTAB-coated NPs and 40 nm PAA-coated NPs was limited to TEM analysis.

3.3.3. Inhibition of Aβ1-40 Monomer Aggregation by Surface Coated Gold NPs
To evaluate the effect of gold NPs on Aβ1-40 aggregation, aggregation of
monomeric protein was induced by continuous agitation, and ThT fluorescence was used
to monitor the formation of β-sheet amyloid aggregates. Aβ1-40 aggregation yielded a
characteristic growth pattern displaying an initial lag phase, indicative of nucleation,
which was followed by rapid aggregate growth that ceased at equilibrium, as evidenced
by plateau of the fluorescence signal (Figure 3.4A).
Aggregation of 40 μM Aβ1-40 monomer was induced in the presence of
20 pM-200 pM NPs.

While none of the NPs examined were capable of impeding

nucleation to extend the lag time, three types of NPs decreased the quantity of aggregates
formed (Figure 3.4A). Addition of 18 nm citrate-coated NPs resulted in a 19.4 ± 8.0%
reduction of the equilibrium fluorescence plateau, and addition of 18 nm PAH-coated
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Figure 3.3: Effect of surface coated NPs on ThT fluorescence detection of Aβ1-40
aggregates: Aβ1-40 fibrils diluted in 40 mM Tris-HCl (pH 8.0) to a final concentration of
5 µM were combined with 8.75 µM ThT to reflect concentrations within diluted samples
used to monitor Aβ1-40 aggregation. Fibrils and ThT were incubated alone or with
20 pM-200 pM NPs for 2 h before fluorescence was evaluated. Results are expressed as
the percent of ThT fluorescence detection relative to control samples. A) Incubation with
18 nm NPs displaying citrate (), CTAB (), PAH (), or PAA () surface
chemistries. B) Incubation with PAA-coated NPs exhibiting 8 nm (), 18 nm (), or
40 nm () diameters. Error bars represent SEM, n=3. *p<0.05, and ***p<0.001
compared to control.
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Figure 3.4: Effect of 18 nm NPs exhibiting varying surface chemistries on Aβ1-40
monomer aggregation: Aβ1-40 monomer diluted to 40 μM in 40 mM Tris-HCl (pH 8.0)
was incubated alone (control,), or in the presence of NPs. Monomer aggregation was
induced under continuous agitation and monitored via ThT fluorescence (F) by periodic
dilution into 10 μM ThT. Fluorescence values are presented as a percentage of the
equilibrium plateau fluorescence observed in the absence of NPs, and time is plotted as a
fraction of the lag time observed in the absence of NPs. A) Aggregation in the presence
of 200 pM NPs displaying citrate (), PAH (), or PAA (), or surface chemistries.
B) Aggregation in the presence of 18 nm PAH-coated NPs at 200 pM (), 100 pM (),
or 20 pM (). Results are representative of three independent experiments.
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NPs reduced β-sheet aggregates by 58.5 ± 9.3% (Table 3.1). The most robust effect was
observed with the addition of 18 nm PAA-coated NPs, which completely abrogated
Aβ1-40 aggregation.
Inhibition of Aβ1-40 monomer aggregation by surface modified NPs was dosedependent (Figure 3.4B, Table 3.1). 18 nm citrate-coated NPs proved ineffective at
concentrations below 200 pM, and inhibition by 18 nm PAH-coated NPs decreased from
58.5 ± 9.3% to 46.9 ± 4.5% and 44.8 ± 4.4% when NP concentration was reduced to
100 pM and 20 pM, respectively. 18 nm PAA-coated NPs, however, continued to impart
complete inhibition at concentrations as low as 20 pM, or a 1:2,000,000
substoichiometric ratio of NPs to Aβ1-40. These results confirm the superior inhibitory
capabilities of PAA-coated NPs. In addition, these inhibitory effects were specific for the
presence of surface coated NPs, as 100 μM of solubilized PAA failed to elicit an
inhibitory effect on aggregation of 40 μM Aβ1-40 (Figure 3.5).
To confirm inhibition of Aβ1-40 monomer aggregation by surface coated gold NPs
and further investigate changes in aggregate morphology, TEM images were acquired
after aggregations reached equilibrium. In the absence of NPs, two distinct aggregates
were observed: long, thin elongated aggregates and short, thick associated aggregates
(Figure 3.6A). This morphology is similar to Aβ aggregates observed in other studies
(17; 82). While Aβ1-40 aggregates formed in the presence of 200 pM 18 nm citrate-coated
NPs exhibited the same morphology, the quantity of aggregates was reduced compared to
the control (Figure 3.6B). A reduction in the quantity of aggregates formed in the
presence of PAH-coated NPs was also evidenced as compared to the control (Figure
3.6C). These results corroborate the plateau reductions observed via ThT fluorescence.
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Table 3.1: Inhibition of Aβ1-40 monomer aggregation by surface modified NPs. a,b

NP type
Diameter Surface modification
Citrate
PAA
18 nm
PAH
PAA
8 nm

[NP] (pM)
20
4.3 ± 2.6
96.5 ± 2.3***
44.8 ± 4.4***
95.1 ± 3.1***

100
0.0 ± 0.0
98.8 ± 0.2***
46.9 ± 4.5***
91.9 ± 4.1***

200
19.4 ± 8.0
94.8 ± 2.7***
58.5 ± 9.3***
94.4 ± 0.5***

***p<0.001 compared to control.
a
Inhibition is expressed as plateau reduction, or the percentage of reduction in the
equilibrium fluorescence plateau compared to the control, calculated as described in
Section 2.7.
b
Parameters are expressed as mean ± SEM, n=3-5.
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Figure 3.5: Effect of solubilized PAA on Aβ1-40 monomer aggregation: Aβ1-40
monomer diluted to 40 μM in 40 mM Tris-HCl (pH 8.0) was incubated alone (control,)
or in the presence of 100 μM PAA (). Monomer aggregation was induced under
continuous agitation and monitored via ThT fluorescence (F) by periodic dilution into
10 μM ThT. Fluorescence and time vales are presented as in Figure 3.4. Results are
representative of three independent experiments.
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Figure 3.6: Morphology of Aβ1-40 aggregates formed in the presence of 18 nm NPs
exhibiting varying surface chemistries: 40 μM Aβ1-40 monomer in 40 mM Tris-HCl
(pH 8.0) was aggregated alone (control, A) or in the presence of 200 pM 18 nm NPs
displaying citrate (B), PAH (C), CTAB (D), or PAA (E) surface chemistries. The control
reaction was monitored via ThT fluorescence, and upon evidence of the equilibrium
plateau samples were gridded and visualized by TEM as described in Section 2.8.
Results are representative of 2 independent experiments. Images are shown relative to a
scale bar of 100 nm.
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Aggregates formed in the presence of CTAB-coated NPs, demonstrated a slight reduction
in aggregate quantity (Figure 3.6D), however, they were not as effective as PAH-coated
NPs.

Furthermore, the absence of fibrillar content detected via TEM when Aβ1-40

monomer was subjected to aggregation conditions in the presence of 200 pM 18 nm
PAA-coated NPs confirms the ability of these NPs to abrogate Aβ1-40 monomer
aggregation (Figure 3.6E).
Aβ1-40 monomer aggregated in the presence of 18 nm cationic NPs, coated with
CTAB or PAH, exhibited morphological changes in aggregate structure. 200 pM CTABcoated NPs induced an increased amount of short, thick aggregates (Figure 3.6D), while
aggregates formed in the presence of 200 pM PAH-coated NPs exhibited an increased
content of long, thin structures (Figure 3.6E). In contrast, anionic citrate-coated NPs
failed to alter aggregate morphology (Figure 3.6B).

Thus, TEM images further

demonstrate the ability of cationic NPs, but not anionic NPs, to influence aggregate
morphology.

3.3.4. Effect of NP Size on Inhibition of Aβ1-40 Monomer Aggregation
Further experimentation with PAA-coated NPs was performed to elucidate the
effect of NP size on inhibitory capabilities. PAA-coated NPs exhibiting diameters of
8 nm, 18 nm, and 40 nm were examined for their ability to attenuate Aβ1-40 monomer
aggregation. Similar to 18 nm PAA-coated NPs, 8 nm PAA-coated NPs reduced the
equilibrium fluorescence plateau by >90% at concentrations as low as 20 pM (Figure 3.7,
Table 3.1), demonstrating their effectiveness as Aβ1-40 aggregation inhibitors. This result
was corroborated by the absence of aggregate material observed via TEM (Figure 3.8B).
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Figure 3.7: Effect of 8 nm PAA-coated NPs on Aβ1-40 monomer aggregation: Aβ1-40
monomer diluted to 40 μM in 40 mM Tris-HCl (pH 8.0) was incubated alone (control,)
or in the presence of 200 pM (), 100 pM (), or 20 pM PAA-coated NPs ().
Monomer aggregation was induced under continuous agitation and monitored via ThT
fluorescence (F) by periodic dilution into 10 μM ThT. Fluorescence and time values are
presented as in Figure 3.4. Results are representative of three independent experiments.
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Figure 3.8: Morphology of Aβ1-40 aggregates formed in the presence of PAA-coated
NPs of varying size: 40 μM Aβ1-40 monomer in 40 mM Tris-HCl (pH 8.0) was
aggregated alone (control, A, D) or in the presence of 200 pM PAA-coated NPs
exhibiting diameters of 8 nm (B), 18 nm (C), or 40 nm (E). The control reaction was
monitored via ThT fluorescence, and upon evidence of the equilibrium plateau samples
were gridded and visualized by TEM as described in Section 2.8. Results are
representative of 2 independent experiments. Images are shown relative to a scale bar of
100 nm (A-C) or 500 nm (D-E).
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In contrast, when NP diameter was increased to 40 nm, PAA-coated NPs were ineffective
at preventing the formation of Aβ aggregates.

Although 40 nm PAA-coated NPs

quenched ThT fluorescence, their inability to prevent aggregate formation was evidenced
by TEM images displaying a similar quantity of Aβ1-40 aggregates formed in the absence
and presence of 200 pM NPs (Figure 3.8E). These results demonstrate that only smaller
PAA-coated NPs are capable of serving as effective inhibitors of Aβ1-40 aggregation.
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3.4. Discussion
The emergence of NPs in medicinal research has led to various applications such
as photo thermal ablation (83), drug delivery (84; 85) and advanced medical imaging (86;
87). With a near limitless library of NPs that can be synthesized with varying core
material, surface chemistry, size, and shape it is important with application in AD that
these NP properties are explored for their therapeutic value. Various types of NPs that
possess potential as Aβ aggregation inhibitors have been developed (74; 75; 81). In this
study, we have characterized the inhibitory capabilities of spherical gold NPs with
varying surface chemistries and diameters. By examining their toxicological effects as
well as their ability to attenuate Aβ aggregation, we identify NP surface chemistry and
size characteristics with potential as an effective AD therapeutic.
Neurotoxicity elicited by synthesized NPs was a function of both surface
chemistry and size. Among 18 nm NPs, only CTAB-coated NPs elicited significant
toxicological effects. Numerous in vitro and in vivo studies have been conducted on the
toxicological effects of NPs (reviewed in (88-90).

While CTAB, a known cellular

membrane detergent, is important in the formation of gold NPs, soluble CTAB left in the
NP solution can lead to toxicity. NPs displaying an inert surface chemistry elicited
varying cellular responses when particle diameter was altered. While 8 nm and 18 nm
PAA-coated particles showed no toxicological effects, larger 40 nm PAA-coated particles
elicited a pronounced decrease in cellular viability. Thus, maintaining a smaller size of
spherical NPs prevents neurotoxicity. This result is in agreement with other reports of
NP toxicity. Mironava et al. demonstrated that 45 nm spherical gold NPs were more
cytotoxic to human dermal fibroblasts then their comparative 13 nm NPs (91). This
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study further determined that altering NP size led to different cellular uptake mechanisms
and thus varied vacuole sequestration, which led to an increase in toxicity for larger
particles.
Moderate inhibitory capabilities were evidenced with the citrate-coated NPs with
19 ± 8% inhibition of aggregation at 200 pM. PAH-coated NPs exhibited 58.5 ± 9.3%
inhibition of aggregation. The most effective inhibition was evidenced with PAA-coated
NPs where complete inhibition was observed at sub-stoichiometric ratios as low as
1:2,000,000 of Aβ:NP. Inhibitory capabilities of NPs are influenced to a greater extent
by surface chemistry than surface charge. While both citrate-coated and PAA-coated
NPs carry a negative charge, PAA-coated NPs are significantly more effective at
inhibiting aggregation. Ikeda et al. discovered that anionic nanogels suppressed Aβ
aggregation at a greater rate than neutral nanogels (92). It was proposed that the anionic
nanogels were able to electrostatically disrupt salt bridge formation resulting in the
inability of fibril formation. This theory can be applied to the inhibitory effects of citratecoated and PAA-coated NPs, with the increased surface charge density of PAA-coated
NPs over citrate-coated NPs leading to increased salt bridge disruption.
Another possible mechanism in which NPs can inhibit Aβ aggregation was
elucidated by Cabaleiro-Lago et al. (74).

When cationic polymeric particles were

introduced to monomeric Aβ, an extension of the lag time to nucleation was evidenced.
It was proposed that absorption of monomeric protein onto the surface of the NPs
depletes monomer within solution leading to an increase in the time required for
nucleation to occur. In this current study, NPs were observed to have no effect on lag
time to aggregate formation. Instead, the quantity of aggregates formed was reduced.
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This contrast suggests that monomeric depletion may not be the mechanism by which the
NPs in this study attenuate Aβ aggregation. Instead, NPs may interact electrostatically
with intermediate aggregates of the protein.
Gold NPs also have the ability to modify fibrillar structure of Aβ aggregates.
Cationic PAH-coated and CTAB-coated NPs elicited the ability to induce distinct
changes in fibrillar morphology. Protein interactions with charged surfaces can have a
pronounced effect on the formation of fibrillar aggregate species. Li et al. demonstrated
that cationic DTAB and a cationic gemini surfactant stimulate distinct changes in fibrillar
aggregate morphology due to the interaction of cationic species with anionic charged
residues within Aβ, leading to misfolding of the protein (93). This study is consistent
with alterations in aggregate morphology induced by cationic CTAB-coated and PAHcoated NPs.

Thus, electrostatic interactions between cationic NPs and anionic Aβ

residues may lead the protein to fold into these distinct conformations.
NP size also plays a role in inhibitory capabilities. While smaller 8 nm PAAcoated NPs were as effective as their 18 nm counterparts, 40 nm PAA-coated NPs
elicited no effect on monomer aggregation. The effects of varying diameter on protein
aggregation have been attributed to NP surface curvature and surface area. Lundqvist et
al. found that larger diameter silica NPs had an increased surface area for human carbonic
anhydrase 1 protein absorption, leading to conformation changes in the protein (94). In
contrast, molecular modeling simulations of NP-protein interactions have demonstrated
that smaller diameter particles can delay protein fibrilization longer than larger particles
(95). Since 40 nm PAA-coated NPs were less effective than their smaller counterparts,
Aβ may not be absorbed onto the NP surface as demonstrated in the work of Lundqvist.

48

These results demonstrate that both surface chemistry and size can modulate the
ability of spherical gold NPs to act as Aβ aggregation inhibitors. Surface chemistry was
found to influence the magnitude of inhibition, with PAA-coated NPs exhibiting the most
pronounced effect. Surface chemistry can also influence in a manner in which NPs
modify aggregate morphology as evidenced with the cationic NPs. Finally, NP size also
influences inhibitory capabilities, as larger particles were ineffective at inhibiting Aβ
aggregation as compared to similarly coated smaller particles. Overall, PAA-coated NPs
18 nm and smaller are superior inhibitors abrogating aggregation at substoichiometric
ratios with the protein.

Together, these findings identify gold NPs as potential

therapeutic agents for the abrogation of Aβ aggregation and provide further insight into
the characteristics needed in the rational design of highly effective NP inhibitors.
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CHAPTER 4
A NOVEL PEPTOID AS AN INHIBITOR OF Aβ AGGREGATION IN ALZHEIMER’S DISEASE
4.1. Introduction
One approach to the inhibition of Aβ aggregation has been the use of small
peptides derived from the Aβ sequence. This approach is based on the idea that the
aggregation of Aβ occurs via self-recognition within the peptide (96). Corroborating this
hypothesis, studies have concluded that peptides homologous to Aβ recognize and bind
Aβ, while amino acid substitutions or additions within these peptides disrupt the
aggregation process. The most effective peptide inhibitors have been those mimicking
the sequence KLVFF, located within the Aβ hydrophobic core (97-100).

Research

suggests that this region of Aβ is responsible for the formation of the protein’s secondary
structure during aggregation (101). In particular, residues 19 and 20 of Aβ, a pair of
phenylalanine residues, are speculated to give rise to π-stacking interactions that may
play a key role in the assembly and stabilization of Aβ aggregates (102). By disrupting
these π-π interactions, inhibition of Aβ aggregation can occur.
One challenge in developing peptides as therapeutic agents is the ease in which
they are degraded in vivo by proteases before reaching their therapeutic target (103). To
decrease protease degradation, researchers have implemented terminal modification by
acetylation or amidation (104), D-amino acid substitutions (105), and tryptophan
replacement of proteolytic sites (106). In each of these studies, an increased half-life was
observed for the modified peptide as compared to its natural counterpart. However, in
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many cases peptide modification also decreased therapeutic activity.

An alternative

approach is to create a peptoid replicate of the peptide of interest. Peptoids differ from
peptides in that the side-chain connectivity is moved from the α-carbon to the amide
nitrogen. This backbone structural modification allows for increased protection from
protease degradation while preserving side chain chemistry to closely maintain the
original structure. In this study, a peptoid based on the amino acid sequence KLVFF was
examined for its ability to disrupt Aβ aggregation. We hypothesize that the peptoid will
alter Aβ aggregation to reduce the physiological activity of Aβ aggregate preparations.
To test this hypothesis, we examined the ability of the peptoid to modulate the formation
of larger Aβ aggregates as well as Aβ oligomers, postulated to be the primary pathogenic
aggregate species, and to attenuate NF-κB activation, a key factor in inflammation related
to AD.
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4.2. Methods & Materials
4.2.1. Peptoid Synthesis
The peptoid examined in this study was synthesized in the laboratory of Dr.
Shannon Servoss (Department of Chemical Engineering, University of Arkansas). This
peptoid (PN) was designed after the KLVFF sequence of Aβ with three additional
C-terminal residues, a spacer and two phenylalanines. Peptoid PN possesses a neutral
spacer residue, an isoleucine, between the two pairs of aromatic phenylalanines (Figure
4.1). PN was synthesized via the submonomer protocol on an ABI 433A automated
peptide synthesizer (Invitrogen, Carlsbad, CA). The Rink amide resin (substitution rate
of ~0.59 mmol/g) was swelled with dimethylformamide (DMF) and the Fmoc protecting
group was removed using 20% piperdine in DMF.

The secondary amine was

bromoacetylated by adding 1.2 M bromoacetic acid in DMF and N,N’-diisopropyl
carboniimide (DIC) at a ratio of 4:1 and vortexing for 60 min. The reaction vessel was
drained and the resin was rinsed with DMF. The desired side chain was integrated by
adding 1 M of primary amine in DMF and vortexing for 90 min. After the synthesis was
complete, the product was cleaved from the resin using a mixture of 95% trifluoroacetic
acid (TFA), 2.5% water, and 2.5% triisopropylsilane (TIS) for 10 min.
Crude product was purified using a Waters Delta 600 reversed-phase high
pressure liquid chromatography (RP-HPLC) system (Milford, MA) equipped with a
Duragel G C18 150 x 20 mm column (5-95% gradient water to acetonitrile). Final purity
was confirmed using a Waters 2695 Separations Module analytical RP-HPLC using a
Duragel G C18 150 x 2.1 mm column (5-95% gradient water to acetonitrile) and Matrix-
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Figure 4.1: Structure of peptoid PN: PN was synthesized analogous to KLVFF, the
hydrophobic core of Aβ. The first five residues of the peptoid mimic KLVFF, while the
c-terminal three residues incorporate a spacer residue, an isoleucine, followed by two
additional aromatic phenylalanines.
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Assisted Laser Desorption/Ionization (MALDI). The secondary structure was determined
to be α-helical via circular dichroism (CD) in methanol.

4.2.2. Aβ1-40 Monomer Aggregation
Monomer aggregations were carried out as described in Section 2.4 with the
inclusion of 100 μM PN. Aggregation was assessed via dot blot analysis as described in
Section 2.6.

4.2.3. Aβ1-42 Oligomerization
Aβ1-42 oligomerization was conducted as described in Section 2.10 with the
inclusion of 2 µM-100 µM PN. After 30 min incubation, oligomers were resolved via
SDS-PAGE and Western blotting following procedures in Section 2.11.

4.2.4. Determination of Aβ1-42 Oligomer Structure by ANS Fluorescence
Aβ1-42 oligomerization was conducted as described in Section 2.10 with the
inclusion of 100 µM PN.

Alterations in oligomer structure, by changes in solvent

exposed hydrophobic regions, were assessed using ANS fluorescence following
procedures in Section 2.12.

4.2.5. XTT Reduction Assay
SH-SY5Y human neuroblastoma cells (Section 2.13) were treated with PN at
20 µM, 10 µM, and 5µM. Cellular viability following peptoid exposure was monitored
via XTT reduction as described in Section 2.14.
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4.2.6. Aβ1-42 Oligomer Activation of NF-κB
Aβ1-42 oligomerization was conducted as described in Section 2.10 with the
inclusion of 100 µM PN. After 30 min, SH-SY5Y cells (Section 2.13) were incubated in
the presence of end products of oligomerization reactions at an oligomer concentration of
2 µM. Media only served as a negative control, while cells treated with 10 Units/well
TNF-α served as a positive control. Following 15 min incubation, cells were prepared
and imaged via confocal microscopy as described in Section 2.15. Image analysis was
conducted as described in Section 2.16.
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4.3. Results
4.3.1. Peptoid PN Inhibits Aβ1-40 Aggregation
To evaluate the effects of this novel peptoid on the late stages of aggregation, an
Aβ1-40 monomer aggregation assay was employed. Monomer aggregation was induced
by continuous agitation in the presence of 150 mM NaCl, and dot blotting with
immunocytochemistry was used to monitor the formation of β-sheet amyloid aggregates.
This approach has become an effective technique to monitor Aβ aggregation (61; 107;
108). Antibody detection of amyloid aggregates can be classified into two categories:
sequence and conformation specific. Antibodies such as 6E10, which are sequence
specific, bind Aβ independent of its secondary structure, and thus recognize both
monomeric and aggregated forms of the protein. In contrast, conformation specific
antibodies recognize structural elements to specifically label aggregate species.

A

common conformational specific antibody for detecting fibrilliar aggregates is OC.
Studies have shown that OC antibody binds to fibrillar aggregates but not to prefibrillar
oligomers (109).

However, the OC antibody can also non-specifically react with

monomeric Aβ. Therefore, LOC (like OC) antibody was developed to lower monomeric
reactivity. The LOC antibody can serve as an excellent indicator of the formation of
fibrillar aggregates during Aβ aggregation (110-112) when ThT detection is insufficient
due to binding competition or interference from potential aggregation inhibitors.
Aggregation of 20 μM Aβ1-40 monomer was induced in the presence of 100 μM PN.
Periodically, samples were dotted onto nitrocellulose membrane and probed with LOC
(Figure 4.2A).

Addition of PN resulted in a modest 24.2 ± 7.8% reduction of the

equilibrium fluorescence plateau as compared to the control (Figure 4.2B).
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Figure 4.2: Effect of peptoid PN on Aβ1-40 monomer aggregation: Aβ1-40 monomer
diluted to 20 μM in 40 mM Tris-HCl (pH 8.0) was incubated alone (control,) or in the
presence of 100 μM PN (). Monomer aggregation was induced under continuous
agitation with 150 mM NaCl and monitored via immunocytochemistry by periodic
dotting onto nitrocellulose membrane (A).
Membranes were developed, and
densiometric analysis was performed as described in Section 2.6 (B). Results are
expressed as a percentage of the control plateau and are representative of two
independent experiments.
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4.3.2. Peptoid PN Alters the Size and Quantity of Aβ1-42 Oligomers
To evaluate the effects of PN on the early stages of aggregation, an Aβ1-42
oligomerization assay was employed. Aβ1-42 deposits first in amyloid plaques and has
been associated with the formation of early stage oligomers (113).

When freshly

solubilized Aβ1-42 was subjected to oligomerization conditions, an even distribution of
oligomers appeared between 20 kDa-100 kDa and 100 kDa-250 kDa (Figure 4.3A).
When PN was introduced, Aβ1-42 oligomers formed were fewer and smaller in size, as
evidenced by smears ceasing at a lower height (Figure 4.3A). Furthermore, a dose
dependent relationship is observed when PN concentration was reduced from 100 μM to
2 μM (Figure 4.3B). To elucidate any changes in the quantity of monomers, as well as
the smallest oligomer species ≤ 20kDa oligomers formed in the presence of 100 μM PN
were resolved. A light band at ~4 kDa indicates the presence of a small quantity of
unreacted monomer, while a dark band at ~12 kDa indicates the pronounced presence of
trimers (Figure 4.4A). Interestingly, the formation of dimers at ~8 kDa is not observed.
However, there was no significant difference in the quantity of monomers, dimers, and
trimers when compared to oligomers formed in the absence of PN (Figure 4.4B).

4.3.3. Peptoid PN modulates Aβ1-42 Oligomer Structure
To characterize changes in Aβ1-42 oligomer conformation due to the presence of
PN, ANS fluorescence was employed. ANS is a naphthaline based compound commonly
used as a fluorescent probe. When ANS is introduced to hydrophobic molecules it
undergoes a conformational change resulting in both blue shift and increased quantum
yield (56). Aβ1-42 Oligomers formed in the presence of PN exhibited increased ANS
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Figure 4.3: Effect of peptoid PN on Aβ1-42 oligomerization: Aβ1-42 oligomers were
prepared, as described in Section 2.10, in the absence (control) or presence of PN. A)
Oligomerization products resolved by SDS-PAGE using a 4-20% Tris-glycine gel were
transferred to nitrocellulose and probed with 6E10. Image is representative of three
independent experiments. B) Densiometric analysis of oligomer species within the size
ranges of 20 kDa-100 kDa () and 100 kDa-250 kDa (Δ), reported as a percentage of the
control. Error bars indicate SEM, n=3. ***p>0.001 versus control for [PN] > 2μM.
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Figure 4.4: Effect of peptoid PN on the formation of Aβ1-42 dimers and trimers:
Aβ1-42 oligomers were prepared, as described in Section 2.10, in the absence (control) or
presence of PN. A) Oligomerization products resolved by SDS-PAGE using a 16.5%
Tris-tricine gel were transferred to nitrocellulose and probed with 6E10 as described in
Section 2.11. Results are representative of three independent experiments. B)
Densiometric analysis of monomer (0 kDa-5 kDa) and trimer (10 kDa-15 kDa) species.
Error bars indicate SEM, n=3.
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fluorescence as compared to oligomers formed alone (Figure 4.5A, B). These results
indicate that the presence of PN leads to an increased exposure of hydrophobic regions
and thus an altered oligomer conformation.

4.3.4. Aβ1-42 Oligomers Formed in the Presence of Peptoid PN Activate NF-κB
Aβ is known to activate NF-κB in neuronal cells (23-26).

Under resting

conditions NF-κB is contained mainly in the cytoplasm, as its nuclear translocation
sequence is masked by IκB. During stressful conditions, cellular signals lead to IκB
degradation, unmasking the NF-κB nuclear translocation sequence to facilitate the
translocation of NF-κB into the nucleus where it initiates the transcription of genes
involved in inflammation and immune response.
In untreated cells, NF-κB is located predominately in the cytoplasm with minimal
levels located within the nucleus (Figure 4.6A, B). After incubation with TNF-α, a
known activator (114), NF-κB translocation into the nucleus is evidenced in SH-SY5Y
cells (Figure 4.6D, E). Digital removal of cytoplasmic NF-κB further verifies nuclear
localized NF-κB (Figure 4.6C, F). To determine if changes in the size and structure of
Aβ1-42 oligomers induced by PN alter NF-κB activation, SH-SY5Y cells were treated for
15 min with Aβ1-42 oligomers formed in the absence or presence of 100 μM PN (Figure
4.7A, B, C). Compared to untreated cells, SH-SY5Y cells exposed to Aβ1-42 oligomers
exhibited increased translocation of NF-κB into the nucleus (Figure 4.7D). Similar levels
of NF-κB translocation were observed with Aβ1-42 oligomers formed in the presence of
PN. To ensure inherent toxicity of PN is not a factor of NF-κB activation SH-SY5Y cells
were treated for 24 h, with PN at concentrations ranging from 5-20 µM, where 10 μM
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represents the concentration equivalent used for cell treatments to activate NF-κB (Figure
4.8).

For all concentrations of PN tested, metabolic activity, measured via XTT

reduction, was >90%, indicating no significant toxicity. These results demonstrate that
alterations in Aβ1-42 oligomer size and structure by PN do not alter NF-κB activation
levels as compared to natively formed oligomers.
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Figure 4.5: Peptoid PN alters Aβ1-42 oligomer structure to expose hydrophobic
regions: Aβ1-42 oligomers were prepared (Section 2.10) in the absence (control, grey) or
presence (red) of 100 μM PN. Oligomers were incubated with 100 μM ANS and
fluorescence was quantified with background subtraction (black) as described in Section
2.12. Representative spectra of native oligomers (A) and oligomers formed in the
presence of PN (B). C) Integrated fluorescence from 450 to 550 nm. Error bars indicate
SEM, n=3.
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Figure 4.6: Activation of NF-κB in SH-SY5Y human neuroblastoma cells: SH-SY5Y
human neuroblastoma cells were incubated for 15 min alone (untreated, A-C) or in the
presence of 10 Units/well TNF-α (D-F). Cells were fixed, stained, and visualized by
confocal microscopy as detailed in Section 2.15. Images shown depict: DAPI nuclear
staining (A, D), NF-κB staining (B, E), or nuclear NF-κB staining extracted via
MATLAB analysis as described in Section 2.16 (C, F). Images shown are medial
sections of a z-series representative of four independent experiments. Scale bar = 50 μm.
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Figure 4.7: Effect of peptoid PN on Aβ1-42 oligomer induced activation of NF-κB:
SH-SY5Y human neuroblastoma cells were incubated for 15 min alone (untreated, A) or
in the presence of 2 μM Aβ1-42 oligomers formed in the absence (PCon, B) or presence
(PN, C) of 100 μM PN. Treatment with TNF-α served as a positive control for NF-κB
activation. Cells were fixed, stained, and visualized by confocal microscopy as detailed
in Section 2.15. Medial section images depict nuclear NF-κB-p65 staining only,
extracted via MATLAB analysis, and are representative of three independent
experiments. Scale bar = 50 μm. D) Nuclear NF-κB / μm3 determined by MATLAB
analysis, as described in Section 2.16, and expressed as a percentage of untreated cells.
Error bars represent SEM, n=3.
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Figure 4.8: Neurotoxicity of peptoid PN: SH-SY5Y human neuroblastoma cells were
incubated for 24 h alone (control) or in the presence of 5-20 µM PN (closed bars).
Treatment with Triton-X served as a positive control (open bar). Cellular metabolic
activity was assessed using XTT reduction. Results are expressed as a percentage of the
control and represent the mean of 3-4 independent experiments, each performed with 6
replicates. Error bars represent SEM. ***p<0.001 as compared to control.
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4.4. Discussion
As there is currently no effective treatment to cure or reverse AD, there is
increasing urgency to identify a therapy. One pathological characteristic of the disease,
Aβ aggregation, has been targeted heavily, with hopes of developing a compound to
disrupt the aggregation process. Peptoids, which are poly-N-subsitituted glycines, have
strong potential as a therapeutic agent. Peptoids are resistant to proteolysis, giving them
an advantage over their peptide counterparts (49). While peptides homologous to the
KLVFF hydrophobic core of Aβ have shown promising results at abrogating Aβ
aggregation (97-100), their ineffectiveness in vivo, which results from their proteolytic
degradation, renders their peptoid counterpart an excellent potential therapeutic
candidate. In this study, we examined a peptoid homologous to KLVFF for its ability to
alter different stages of Aβ aggregation as well as associated NF-κB activation, which has
been suggested to play an important role in inflammation.
In patients with AD, in vivo analysis has demonstrated that both Aβ1-40 and Aβ1-42
aggregates are present within neuronal plaques (115). While Aβ1-40 is the more abundant
isoform, aggregates of Aβ1-42 form quicker and have a higher neurotoxicity (116-119).
Soluble Aβ oligomers have been implicated as the most neurotoxic Aβ species (13), thus
inhibition of the formation of oligomers could lead to reduced toxicological effects.
Here, peptoid PN, mimicking the hydrophobic core of Aβ, was evaluated for its ability to
disrupt the formation of Aβ1-42 oligomers. PN reduced the size and quantity of oligomers
larger than 20 kDa formed (Figure 4.3).

However, PN was ineffective at eliciting

changes in the formation of oligomers smaller than 20 kDa (Figure 4.4), indicating that it
interacts with the protein after the initial formation of small oligomers. PN was also

67

evaluated for its ability to modulate Aβ1-40 monomer aggregation. However, it only
modestly reduced the formation of fibrillar aggregates (Figure 4.2). Several studies have
examined the ability of modified peptides to interfere with Aβ aggregation. Findeis et al.
demonstrated the ability of Cholyl-LVFFA-OH to inhibit the fibrillogenesis of Aβ1-40
(120). Austen et al. also demonstrated the ability of peptides to interfere with the
oligomerization of Aβ1-42 and the aggregation of Aβ1-40 with the inclusion of the peptide
RGKLVFFGR-NH2 (121).

Gordon et al. also provided evidence that N-methylated

peptides analogous to the hydrophobic core of Aβ can both disrupt the formation of
fibrils and dissociate pre-formed fibrils (122). These results corroborate that peptide or
peptoid inhibitors designed after the hydrophobic core of Aβ are effective at disrupting
Aβ aggregation.
To gain further insight into the ability of PN to alter oligomer structure, we
employed ANS spectroscopy to compare the exposure of hydrophobic residues within
Aβ1-42 oligomers formed in the absence or presence of PN. Oligomers formed in the
presence of PN exhibited enhanced ANS fluorescence, indicating an increase in solvent
exposed hydrophobic regions (Figure 4.5).

Changes in surface hydrophobicity of

proteins can have negative effects on cells. Using two types oligomers formed from the
N-terminal domain of the Escherichia coli HypF, differing in hydrophobicity, Campioni
et al. discovered that oligomers with increased surface hydrophobicity disrupted SHSY5Y cell membranes, causing an influx of Ca2+, which lead to cell death (123).
Furthermore, Goransson et al. demonstrated that Aβ aggregate species with increased
surface hydrophobicity were responsible for cell death in cultured neuronal cells (124).
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To evaluate the cellular effects of PN, oligomers formed in its presence were
examined for their ability to activate NF-κB, which is known to play a key role in ADassociated inflammatory responses. SH-SY5Y human neuroblastoma cells exposed to
Aβ1-42 oligomers formed in the presence of PN exhibited an increase in NF-κB activation
similar to oligomers formed alone (Figure 4.7). Furthermore, NF-κB activation was not
occurring due to inherent toxicity from PN, as SH-SY5Y cells treated with PN (5-20 µM)
exhibited no decrease in metabolic activity (Figure 4.8). The effects of peptoids on
cultured neurons have also been observed by Chen et al. Using medium spiny neurons,
<5% toxicity was induced by poly-Q binding peptoids being evaluated for their ability to
inhibit Huntingtin protein in Huntington’s disease (125). These results indicate that PN
induced changes in oligomer size and conformation do not decrease the ability of
oligomers to activate NF-κB.
Together, these results demonstrate that peptoid PN can alter the aggregation of
Aβ but not the physiological activity of aggregates formed.

While PN does not

significantly decrease the formation of fibrillar Aβ1-40 aggregates, it does lead to the
assembly of fewer and smaller Aβ1-42 oligomers. PN was also demonstrated to alter the
structure of Aβ1-42 oligomers by increasing the amount of solvent exposed hydrophobic
residues. Finally, while PN was shown to be non-toxic to SH-SY5Y cells, oligomers
formed in the presence of PN caused activation of NF-κB, suggesting that alterations in
oligomer size and hydrophobicity by PN do not attenuate cellular responses.
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CHAPTER 5
MODULATION OF A AGGREGATION BY PEPTOIDS IS EFFECTED BY CHARGED RESIDUES
WITHIN THE PEPTOID SEQUENCE

5.1. Introduction
Electrostatic interactions are believed to play a role in the aggregation propensity
of Aβ (126). Disrupting these interactions can serve as a therapeutic strategy in the
rational design of Aβ aggregation inhibitors. Charged small molecules have the ability to
disrupt aggregate formation. Anionic sulfonate compounds (127) and Congo red (128130) both disrupt Aβ aggregation in vitro. Cationic surfactants, such as hexadecyl-Nmethylpiperidinium bromide, also inhibit Aβ fibril formation, possibly by interacting
with charged Aβ binding sites necessary for aggregation (131).
In Chapter 4, we demonstrated the ability of a novel peptoid to interfere with the
aggregation of Aβ1-40 and Aβ1-42. To enhance the effectiveness of peptoids as inhibitors
of Aβ aggregation, we examined the effects of modifying charged groups within the
peptoid sequence.

We hypothesize that the addition of charges within the peptoid

sequence will increase inhibitory capabilities toward aggregation.

70

5.2. Methods & Materials
5.2.1. Peptoid Synthesis
Peptoids P+ and P- were synthesized in the laboratory of Dr. Shannon Servoss
(Department of Chemical Engineering, University of Arkansas) as described in Section
4.2.1. P+ and P- were designed to have the same structure as PN with the neutral spacer
between the two pairs of phenylalanine residues replaced by a positively charged lycine
residue (P+, Figure 5.1A) or a negatively charged glutamic acid residue (P-, Figure 5.1B).

5.2.2. Aβ1-40 Monomer Aggregation
Monomer aggregations were carried out as described in Section 2.4 with the
inclusion of 100 μM P+ or P-.

Aggregation was assessed via dot blot analysis as

described in Section 2.6.

5.2.3. Aβ1-42 Oligomerization
Aβ1-42 oligomerization was conducted as described in Section 2.10 with the
inclusion of 2 µM-100 µM P+ or P-. After 30 min incubation, oligomers were resolved
via SDS-PAGE and Western blotting following procedures in Section 2.10.

5.2.4. Determination of Aβ1-42 Oligomer Structure by ANS Fluorescence
Aβ1-42 oligomerization was conducted as described in Section 2.10 with the
inclusion of 100 µM P+ or P-. Alterations in oligomer structure, by changes in solvent
exposed hydrophobic regions, were assessed using ANS fluorescence following
procedures in Section 2.12.

71

Figure 5.1: Structure of peptoids P+ and P-: Peptoids P+ and P- were synthesized
analogous to KLVFF, the hydrophobic core of Aβ. The first five residues of each peptoid
mimic KLVFF, while the C-terminal three residues incorporate a positively charged
lysine (A, P+) or a negatively charged glutamic acid (B, P-) followed by two additional
aromatic phenylalanines.
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5.2.5. XTT Reduction Assay
SH-SY5Y human neuroblastoma cells (Section 2.13) were treated with P+ or P- at
20 µM, 10 µM, and 5µM. Cellular viability following peptoid exposure was monitored
via XTT reduction as described in Section 2.14.

5.2.6. Aβ1-42 Oligomer Activation of NF-κB
Aβ1-42 oligomerization was conducted as described in Section 2.10 with the
inclusion of 100 µM P+ or P-.

After 30 min, SH-SY5Y cells (Section 2.13) were

incubated in the presence of end products of oligomerization reactions at an oligomer
concentration of 2 µM. Media only served as a negative control, while cells treated with
10 Units/well TNF-α served as a positive control. Following 15 min incubation, cells
were prepared and imaged via confocal microscopy as described in Section 2.15. Image
analysis was conducted as described in Section 2.16.
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5.3. Results
5.3.1. Peptoid P+, but not Peptoid P-, Inhibits the Fibrilization of Aβ1-40
Aggregation of monomeric Aβ1-40 was employed to initially investigate the
inhibitory capabilities of P+ and P-. Aggregation of 20 μM Aβ1-40 monomer was induced
via continuous agitation and 150 mM NaCl in the presence of 100 μM P+ or P-.
Periodically, samples were dotted onto nitrocellulose membrane and probed with LOC
(Figure 5.2A). Addition of P+ resulted in a 57.4 ± 23.6% reduction of the equilibrium
fluorescence plateau as compared to the control (Figure 5.2B). In contrast, P- promoted
the formation of fibrillar aggregates (Figure 5.2B). These results suggest that inclusion
of a negative charge within the peptoid sequence removes the modest inhibitory
capabilities associated with homologous peptoid PN (Figure 4.2), while inclusion of an
additional positive charge imparts superior inhibition.

5.3.2. Peptoids P+ and P- Both Alter the Size and Quantity of Aβ1-42 Oligomers
Aβ1-42 oligomerization was employed to examine P+ and P- for their ability to
modify early stages of aggregation. When freshly solubilized Aβ1-42 was subjected to
oligomerization conditions, an even distribution of oligomers appeared between 20 kDa100 kDa and 100 kDa-250 kDa. Aβ1-42 oligomers, formed in the presence of P+ and P-,
were fewer and smaller in size as compared to the control (Figures 5.3A, 5.4A). Dose
dependence was observed when P+ and P- concentrations were reduced from 100 μM to
2 μM (Figures 5.3B and 5.4B). Furthermore, this dose dependence revealed that P- was
less effective than P+ at reducing oligomer quantity. To elucidate any changes induced
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Figure 5.2: Effect of peptoids P+ and P- on Aβ1-40 monomer aggregation: Aβ1-40
monomer diluted to 20 μM in 40 mM Tris-HCl (pH 8.0) was incubated alone (control,)
or in the presence of 100 μM P+ () or P- (). Monomer aggregation was induced
under continuous agitation with 150 mM NaCl and monitored via immunocytochemistry
by periodic dotting onto nitrocellulose membrane (A). Membranes were developed and
densiometric analysis was performed as described in Section 2.6 (B). Results are
expressed as a percentage of the control and are representative of two independent
experiments.
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Figure 5.3: Effect of peptoid P+ on Aβ1-42 oligomerization: Aβ1-42 oligomers were
prepared in the absence (control) or presence of P+. A) Oligomerization products
resolved by SDS-PAGE using a 4-20% Tris-glycine gel were transferred to nitrocellulose
and probed with 6E10. Image is representative of three independent experiments. B)
Densiometric analysis of oligomer species within the size ranges of 20 kDa - 100 kDa
() and 100 kDa -250 kDa (Δ), reported as a percentage of the control. Error bars
indicate SEM, n=3. For 20 kDa-100 kDa ** p<0.01, *** p<0.001; for 100 kDa-250 kDa
+ p<0.05, ++ p<0.01 as compared to the control.
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Figure 5.4: Effect of peptoid P- on Aβ1-42 oligomerization: Aβ1-42 oligomers were
prepared, as described in Section 2.10, in the absence (control) or presence of P-. A)
Oligomerization products resolved by SDS-PAGE using a 4-20% Tris-glycine gel were
transferred to nitrocellulose and probed with 6E10. Image is representative of three
independent experiments. B) Densiometric analysis of oligomer species within the size
ranges of 20 kDa-100 kDa () and 100 kDa-250 kDa (Δ), reported as a percentage of the
control. Error bars indicate SEM, n=3. For 20 kDa-100 kDa * p<0.05, ** p<0.01 as
compared to the control.
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Figure 5.5: Effect of peptoids P+ and P- on the formation of Aβ1-42 dimers and
timers: Aβ1-42 oligomers were prepared in the absence (control) or presence of P+ (blue)
or P- (green). A) Oligomerization products resolved by SDS-PAGE using a 16.5% Tristricine gel were transferred to nitrocellulose and probed with 6E10. Results are
representative of three independent experiments. B) Densiometric analysis of monomer
(0 kDa-5 kDa), and trimer (10 kDa-15 kDa). Error bars indicate SEM, n=3.
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by P+ and P- in the quantity of monomers as well as the smallest oligomers, aggregate
species smaller than 20 kDa were resolved.

A light band at ~4 kDa indicates the

presence of a small quantity of unreacted monomer, while a dark band at ~12 kDa
indicates the pronounced presence of trimers (Figure 5.5A). Interestingly, the formation
of dimers at ~8 kDa is not evidenced. Unlike higher order oligomers, however, no
change is observed in the quantity of monomers, dimers, or trimers formed in the
presence of P+ or P- (Figure 5.5B).

5.3.3. Peptoid P+ but not Peptoid P- Modulates Aβ1-42 Oligomer Structure
ANS fluorescence was employed to characterize changes in oligomer structure
due to the presence of peptoids P+ or P-. Oligomers formed in the absence of peptoid
exhibit low amounts of solvent exposed hydrophobic residues, as evidenced by low ANS
fluorescence (Figure 5.6A). However, ANS fluorescence of oligomers formed in the
presence of P+ was significantly increased indicating an altered structure with more
exposed hydrophobic residues (Figure 5.6A, B). In contrast, P- had no significant effect
on oligomer structure, with ANS fluorescence levels comparable to the control (Figure
5.6A, C).

5.3.4. Aβ1-42 Oligomers Formed in the Presence of Peptoids P+ and P- Activate
NF-κB
To determine whether peptoid-induced changes in the size and structure of Aβ1-42
oligomers can alter Aβ-induced NF-κB activation, SH-SY5Y human neuroblastoma cells
were treated for 15 min with Aβ1-42 oligomers formed in the absence or presence of
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100 μM P+ or P-. Compared to untreated cells (Figure 5.7A), SH-SY5Y cells exposed to
Aβ1-42 oligomers exhibited increased translocation of NF-κB into the nucleus (Figure
5.7B).

Similar levels of NF-κB translocation were observed with Aβ1-42 oligomers

formed in the presence of P- (Figure 5.7D), while SH-SY5Y cells treated with oligomers
formed in the presence of P+ demonstrated a small but insignificant increase in NF-κB
activation as compared to the control (Figure 5.7C, E).
To ensure that inherent toxicity of P+ and P-, does not account for NF-κB
activation, SH-SY5Y cells were treated for 24 h with P+ and P- at concentrations ranging
from 5-20 µM, where 10 μM represents the concentration equivalent used for cell
treatments to activate NF-κB (Figure 5.8). For all concentrations of P+ and P- tested,
metabolic activity, measured via XTT reduction, was >90%, indicating no significant
toxicity. Together, these results demonstrate that size and structural differences in Aβ1-42
oligomers induced by P+ and P- do not significantly alter Aβ-induced NF-κB activation.
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Figure 5.6: Peptoid P+, but not peptoid P-, alters Aβ1-42 oligomer structure to expose
hydrophobic regions: Aβ1-42 oligomers were prepared, as described in Section 2.10, in
the absence (control, grey) or presence of 100 μM P+ (blue) or P- (green). Oligomers
were incubated with 100 μM ANS and fluorescence was quantified with background
subtraction (black). Representative spectra of native oligomers (A) and oligomers
formed in the presence of P+ (B) or P- (C). D) Integrated fluorescence from 450 to 550
nm. Error bars indicate SEM, n = 3. ***p<0.001 as compared to the control.
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Figure 5.7: Effect of peptoids P+ and P- on Aβ oligomer-induced activation of
NF-κB: SH-SY5Y human neuroblastoma cells were incubated for 15 min alone
(untreated, A) or in the presence of 2 μM Aβ1-42 oligomers formed in the absence (PCon,
B) or presence of 100 μM P+ (P+, C) or 100 μM P- (P-, D). Treatment with TNF-α
served as a positive control for NF-κB activation. Cells were fixed, stained, and
visualized by confocal microscopy as described in Section 2.15. Medial section images
depict nuclear NF-κB-p65 staining only, extracted via MATLAB analysis, and are
representative of 2-3 independent experiments, each performed with 2-3 replicates. Scale
bar=50 μm. E) Nuclear NF-κB / μm3 determined by MATLAB analysis as described in
Section 2.16, and expressed as a percentage of untreated cells. Error bars represent SEM,
n=3.
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Figure 5.8: Neurotoxicity of peptoids P+ and P-: SH-SY5Y human neuroblastoma
cells were incubated for 24 h alone (control) or in the presence of 5-20 µM P+ (blue) or
P- (green). Treatment with Triton-X served as a positive control (open bar). Cellular
metabolic activity was assessed using XTT reduction. Results are expressed as a
percentage of the control and represent the mean of 3-4 independent experiments, each
performed with 6 replicates. Error bars represent SEM. ***p<0.001 as compared to the
control.
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5.4. Discussion
Previous studies have shown that small molecules incorporating charges can
inhibit Aβ aggregation through electrostatic disruptions of protein folding (126-131).
Therefore, introducing additional charged residues into the structure of the peptoid PN,
examined in Chapter 4, may increase inhibitory effects. In this study, we examined the
effects of introducing charged residues within a peptoid homologous to KLVFF on the
ability to alter different stages of Aβ aggregation as well as associated NF-κB activation.
Inhibition of Aβ1-40 aggregation by two peptoids incorporating charged residues
was first evaluated. The peptoid incorporating an additional positive charge, P+, reduced
the formation of fibrillar aggregates by 57.4 ± 23.6%, while the peptoid incorporating an
additional negative charge, P-, had no effect on aggregation (Figure 5.2). These results
are in agreement with reports that charge modified KLVFF peptides can interfere with
Aβ1-40 aggregation. Bett et al. examined the abilities of various KLVFF peptides with Nand C- terminus charge additions to inhibit Aβ1-40 aggregation (132). The addition of
positively charged arginine to the C-terminus of KLVFF significantly reduced Aβ1-40
aggregation by 80%. However, when arginine was moved to the N-terminus or contained
on both termini, its effectiveness against aggregation decreased. In contrast, Lowe et al.
reported that KLVFF-E4, containing negatively charged glutamic acid, promoted fibrillar
aggregate growth similar to the slight promotion of aggregate formation by P- observed
in the current study (98). Thus, our results corroborate prior findings that peptide mimics
containing a positive charge are superior inhibitors of Aβ1-40 aggregation, and extend
these findings to include peptoid inhibitors.
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To further examine the effects of charged peptoids on the Aβ aggregation
pathway, oligomerization of Aβ1-42 was employed to evaluate the ability of P+ and P- to
interfere within early stages of aggregation. Both P+ and P- were able to reduce the size
and quantity of oligomers larger than 20 kDa (Figure 5.3, 5.4). In contrast, both P+ and
P- were ineffective at eliciting changes in the formation of oligomers smaller than 20 kDa
(Figure 5.5), suggesting that these peptoids interact not with monomer, but with lower
order oligomer structures. To gain further insight into the ability of P+ and P- to alter
oligomer structure, ANS spectroscopy was employed to compare the exposure of
hydrophobic residues within Aβ1-42 oligomers formed in the absence or presence of P+ or
P-. P+ significantly altered the structure of oligomers formed in its presence, while Phad little effect (Figure 5.6).
To evaluate the physiological implications of peptoid modulation of Aβ-induced
oligomerization, Aβ1-42 oligomers formed in the presence of P+ and P- were evaluated for
their ability to activate NF-κB. P+, but not P-, slightly but insignificantly increased
oligomer activation of NF-κB (Figure 5.7). Like PN, P+ and P- failed to alter XTT
reduction in SH-SY5Y human neuroblastoma cells (Figure 5.8) demonstrating that
NF-κB activation is not a result of peptoid toxicity. These results indicate that neither
changes in oligomer size nor hydrophobicity due to the presence of charged peptoids
have an effect on NF-κB activation.
These results demonstrate that a peptoid homologous to the hydrophobic core of
Aβ and incorporating an additional positive charge can alter the aggregation of Aβ. This
peptoid has the ability to decrease the formation of fibrillar Aβ1-40 aggregates, as well as
alter both the size and structure of Aβ1-42 oligomers. In contrast, a similar peptoid
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incorporating a negative charge reduces Aβ1-42 oligomer size and quantity, but is
ineffective at abrogating Aβ1-40 aggregation or altering Aβ1-42 oligomer structure. Neither
peptoid, however, was able to alter NF-κB activation by oligomeric Aβ1-42 aggregates.
Overall, these results demonstrate that the role of charged residues in peptoid modulation
of Aβ aggregation and further demonstrate that changes in oligomer size and structure are
insufficient to alter Aβ aggregate physiological activity.
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CHAPTER 6
CONCLUSIONS
Development of a treatment for AD is imperative as the number of AD diagnoses
increases every year. Therapeutic intervention targeting Aβ aggregation serves as one
viable treatment course. In this work, we demonstrated the ability of gold nanoparticles
and peptoids to act as novel inhibitors of Aβ aggregation.
Within Chapter 3, we examined the ability of gold NPs with varying surface
chemistries and diameters to abrogate Aβ aggregation. Inhibitory capabilities exhibited a
dependence on surface chemistry, including surface charge. NPs coated with the anionic
polymer PAA exhibited complete inhibition of aggregation at a substoichiometric ratio of
NPs:Aβ of 1:2,000,000. Ratios this low have never been evidenced for potential Aβ
inhibitors, rendering NPs as potentially effective therapeutic agents. While cationic NPs
were less effective than their anionic counterparts at inhibition Aβ aggregation, they did
impart mechanistic specific changes in fibril morphology.

NP diameter was also

evidenced to play a role in the inhibitory capabilities of NPs. As the diameter of PAAcoated NPs increased, inhibitory capabilities decreased, suggesting that smaller NPs are
better suited as Aβ aggregation inhibitors. With the near limitless library of NPs that can
be synthesized, it is important to determine specific characteristics of NPs that enhance
their ability to inhibit Aβ aggregation. The results presented in this study demonstrate
that surface chemistry, charge, and diameter are important characteristics to consider
when designing effective NP inhibitors of Aβ aggregation.
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In Chapters 4 and 5, we examined the ability of peptoids to inhibit the aggregation
of Aβ. First, we demonstrated the ability of a peptoid homologous to the hydrophobic
core of Aβ, and incorporating additional aromatic phenylalanine residues, to decrease the
size and quantity of Aβ1-42 oligomers while also altering their conformation by exposing
hydrophobic residues. However, these changes in oligomer structure had no effect on
diminishing Aβ1-42 oligomer-induced NF-κB activation.

To further characterize

properties that enhance peptoid ability to inhibit aggregation, additional positive or
negative charges were incorporated within the peptoid sequence. Inclusion of a positive
charge between two pairs of phenylalanine residues increased inhibitory capabilities and
induced changes in oligomer conformation, while the inclusion of a negative charge at
the same location reduced inhibitory effectiveness and failed to alter oligomer structure.
However, these peptoids with differing effects on oligomer structure both had no effect
on attenuating Aβ1-42 oligomer-induced NF-κB activation. Thus, the charge addition
associated with an effective peptoid inhibitor is in contrast to that of an effective NP
inhibitor, where an anionic surface charge proved to be most advantageous. This contrast
suggests that NPs and peptoids disrupt Aβ aggregation by different mechanisms.
Overall, this study demonstrates the effectiveness of two novel inhibitors of Aβ
aggregation and their potential as therapeutic treatments.
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CHAPTER 7
FUTURE WORK
The rational design of a treatment for AD must incorporate the best attributes of
different potential therapeutics. PAA-coated NPs showed superior inhibitory capabilities,
however their surface coating is only electrostatically contained onto the particle surface.
Unfortunately, this may lead to dissociation of the particle surface coating when
introduced into the body.

The inherent properties of gold allow molecules to be

covalently functionalized onto the particle surface through Au-S interactions. Therefore,
covalent attachment of PAA onto the nanoparticle surface may increase therapeutic
stability when introduced into the body.
This same functionalization also imparts NPs with the ability to covalently attach
different molecules at the surface. Aggregation inhibitors, such as peptoids, can be
functionalized onto a NP surface to give them access across the BBB. Also, as seen with
PAA, surface functionalization of molecules onto NP surfaces can increase inhibitory
capabilities by creating a high local surface concentration. Therefore, the therapeutic
abilities of peptoids might be enhanced by functionalizing them onto gold NPs.
Conjugation chemistry allows for the ability to control the orientation of the peptoid on
the NP surface, determining orientation specific inhibitory capabilities. Also, inclusion
of a PEG spacer can allow for changes in peptoid flexibility based on its distance from
the NP surface.

Altogether, these future design possibilities could lead to the
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development of gold NP-peptoid complexes that serve as superior therapeutic agents for
the treatment of AD.
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